Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Feb;18(2):189-97.
doi: 10.1517/13543780802691068.

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

Affiliations
Review

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

Dietmar W Siemann et al. Expert Opin Investig Drugs. 2009 Feb.

Abstract

Vascular-disrupting strategies impair a tumor's blood vessel network, which is essential for tumor progression and metastasis. Vascular-disrupting agents (VDAs) cause a rapid and selective vascular shutdown in tumors to produce extensive secondary neoplastic cell death due to ischemia. A lead agent in this therapeutic strategy is the tubulin depolymerizing agent combretastatin-A4 phosphate (CA4P). Used alone, CA4P induces extensive necrosis in a wide variety of preclinical cancer models and significant blood flow reductions in the patient tumors. Preclinical and clinical data further indicate that CA4P can effectively be combined with chemotherapy or radiotherapy. Finally, the potential of combining VDAs with antiangiogenic therapies has shown considerable promise in preclinical models and such combinations are now beginning to be evaluated in patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Molecular structure of CA4P.tris
Figure 2
Figure 2
Histological assessment of CaNT tumours that were evaluated at various times after treatment with a 100 mg/kg dose of CA4P. a) Untreated control, b) – d) 1, 3, and 4 days post CA4P exposure, respectively. Figure was modified from (21).
Figure 3
Figure 3
Effect of CA4P treatment alone or in combination with Avastin on renal cell carcinoma (Caki-1) xenograft growth. CA4P (100 mg/kg) was given Mondays, Wednesdays, and Fridays for 2 weeks. Avastin treatment (2 mg/kg) was administered daily (Monday through Friday) for 2 weeks. Data shown are a) the growth of the median tumors and b) the median, 75th, and 90th percentiles of responses of tumors treated at a starting size of 200 mm3. Results in mice treated with combination therapy were significantly greater than those obtained in mice treated only with a single therapy (p<0.05, Wilcoxon rank sum test). Figure was modified from (36).

Similar articles

Cited by

References

    1. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989;45:209–211. - PubMed
    1. Lin CM, Singh SB, Chu PS, Dempcy RO, et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol. 1988;34:200–208. - PubMed
    1. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, LoRusso PM. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 2005;11:416–420. - PubMed
    1. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001;21:93–102. - PubMed
    1. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Brit J Cancer. 1999;80:57–64. - PubMed

MeSH terms

LinkOut - more resources